Heated amphotericin to treat leishmaniasis
Authors:
- Jacques BolardJBJacques Bolard
- Jean Dupouy-CametJDJean Dupouy-Camet
- 1 April 2003
- journal article
- editorial
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 3 (4) , 188
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- How better drugs could change kala‐azar control. Lessons from a cost‐effectiveness analysisTropical Medicine & International Health, 2002
- Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agendaThe Lancet Infectious Diseases, 2002
- A policy for leishmaniasis with respect to the prevention and control of drug resistanceTropical Medicine & International Health, 2001
- Heat Treatment of Amphotericin B Modifies Its Serum Pharmacokinetics, Tissue Distribution, and Renal Toxicity following Administration of a Single Intravenous Dose to RabbitsAntimicrobial Agents and Chemotherapy, 2001
- Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, IndiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Mild Heating of Amphotericin B-Desoxycholate: Effects on Ultrastructure, In Vitro Activity and Toxicity, and Therapeutic Efficacy in Severe Candidiasis in Leukopenic MiceAntimicrobial Agents and Chemotherapy, 2000
- Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovaniAntimicrobial Agents and Chemotherapy, 1999
- Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic indexAntimicrobial Agents and Chemotherapy, 1997